Diabetic rats given MOTS-c had lower blood sugar levels after fasting, showing better control of glucose.
Scientific Claim
In a rat model of type 2 diabetes, daily MOTS-c treatment (15 mg/kg for 3 weeks) was associated with reduced fasting blood glucose levels from 15.2 ± 1.0 mmol/L to 10.3 ± 0.8 mmol/L compared to untreated diabetic rats.
Original Statement
“Untreated diabetic rats had notably higher fasting glucose levels than control and MOTS-c-treated diabetic rats, with no difference between the latter two groups (Figure 1A).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study is an animal cohort, so 'was associated with' is appropriate. The claim correctly states the association without implying causation.
Evidence from Studies
Supporting (1)
Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart